Co-administration of expanded PD-1+ T cells and anti-PD-L1 further improved survival and eliminated myeloma in 100% of mice (Fig. 4b), demonstrating that ongoing PD-L1 blockade was needed to achieve optimal efficacy. Here, CD274 is linked to plasma cell myeloma.